Karyopharm Therapeutics Inc (KPTI):企業の財務・戦略的SWOT分析

◆英語タイトル:Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1646
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Karyopharm Therapeutics Inc (KPTI) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Karyopharm Therapeutics Inc (Karyopharm Therapeutic) discovers and develops novel drugs for the treatment of various cancer types. The company develops small molecule selective inhibitors of nuclear export compounds that combat the nuclear export of XPO1 protein. Its pipeline drug candidates include selinexor, verdinexor, eltanexor, and oral KPT-9274. Karyopharm drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and gynecological malignancies. The company has operations in the US, Israel and Germany. Karyopharm is headquartered in Newton, Massachusetts, the US.

Karyopharm Therapeutics Inc Key Recent Developments

Mar 12,2020 Karyopharm expands executive leadership team with the appointment of John Demaree as Chief Commercial Officer
Feb 13,2020 Karyopharm reports fourth quarter and full year 2019 financial results and highlights recent company progress
Nov 04,2019 Karyopharm reports third quarter 2019 financial results and highlights recent company progress
May 09,2019 Karyopharm reports first quarter 2019 financial results and highlights recent company progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Karyopharm Therapeutics Inc – Key Facts
Karyopharm Therapeutics Inc – Key Employees
Karyopharm Therapeutics Inc – Key Employee Biographies
Karyopharm Therapeutics Inc – Major Products and Services
Karyopharm Therapeutics Inc – History
Karyopharm Therapeutics Inc – Company Statement
Karyopharm Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Karyopharm Therapeutics Inc – Business Description
R&D Overview
Karyopharm Therapeutics Inc – Corporate Strategy
Karyopharm Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Karyopharm Therapeutics Inc – Strengths
Karyopharm Therapeutics Inc – Weaknesses
Karyopharm Therapeutics Inc – Opportunities
Karyopharm Therapeutics Inc – Threats
Karyopharm Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Karyopharm Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 12, 2020: Karyopharm expands executive leadership team with the appointment of John Demaree as Chief Commercial Officer
Feb 13, 2020: Karyopharm reports fourth quarter and full year 2019 financial results and highlights recent company progress
Nov 04, 2019: Karyopharm reports third quarter 2019 financial results and highlights recent company progress
May 09, 2019: Karyopharm reports first quarter 2019 financial results and highlights recent company progress
Mar 01, 2019: Karyopharm reports fourth quarter and full year 2018 financial results and provides corporate update
Feb 25, 2019: Karyopharm strengthens management team with appointment of Michael P. Mason as chief financial officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Karyopharm Therapeutics Inc, Key Facts
Karyopharm Therapeutics Inc, Key Employees
Karyopharm Therapeutics Inc, Key Employee Biographies
Karyopharm Therapeutics Inc, Major Products and Services
Karyopharm Therapeutics Inc, History
Karyopharm Therapeutics Inc, Subsidiaries
Karyopharm Therapeutics Inc, Key Competitors
Karyopharm Therapeutics Inc, Ratios based on current share price
Karyopharm Therapeutics Inc, Annual Ratios
Karyopharm Therapeutics Inc, Annual Ratios (Cont...1)
Karyopharm Therapeutics Inc, Interim Ratios
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Karyopharm Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Karyopharm Therapeutics Inc, Performance Chart (2015 - 2019)
Karyopharm Therapeutics Inc, Ratio Charts
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Karyopharm Therapeutics Inc (KPTI):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Energy Conservation and Environmental Protection Group-エネルギー分野:企業M&A・提携分析
    Summary China Energy Conservation and Environmental Protection Group (CECEP) is a clean technology company that offers energy conservation, emission reduction and environment protection services. The company provides clean energy, energy saving, environmental protection, integrated services and reso …
  • Sembcorp Industries Ltd (U96)-エネルギー分野:企業M&A・提携分析
    Summary Sembcorp Industries Limited (Sembcorp) is a diversified energy, water and marine company. The company’s utilities division provides energy and water to industrial and municipal customers. Its energy operations include power generation, steam production and supply and natural gas import suppl …
  • Medicines for Malaria Venture-製薬・医療分野:企業M&A・提携分析
    Summary Medicines for Malaria Venture (MMV) is a drug development and manufacturing company that discovers, develops and delivers anti malarial drugs. The company offers products that provide efficacy against drug-resistant strains of plasmodium falciparum, potential for intermittent treatments, saf …
  • Faron Pharmaceuticals Oy (FARN):製薬・医療:M&Aディール及び事業提携情報
    Summary Faron Pharmaceuticals Oy (Faron) is a clinical stage biopharmaceutical company that conducts clinical stage drug discovery and development. The company's pipeline products focus on cute organ traumas, vascular damage and cancer immunotherapy. It offers Traumakine, that helps to prevent vascu …
  • Edelweiss Financial Services Ltd:企業のM&A・事業提携・投資動向
    Edelweiss Financial Services Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Edelweiss Financial Services Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • Pharmathen Pharmaceuticals SA-製薬・医療分野:企業M&A・提携分析
    Summary Pharmathen Pharmaceuticals SA (Pharmathen) is a healthcare products provider that develops and markets generic products. The company’s products include oral antiplatelet agent, bactericidal cephalosporin antibiotic, retinoid, beta1-selective adrenergic receptor blocking agent, and others. It …
  • Cayenne Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Cayenne Medical Inc (Cayenne Medical), a subsidiary of Zimmer Biomet Holdings Inc, is a soft-tissue reconstruction service provider. The company provides knee and shoulder implant products. It offers products such as aperfix femoral, aperfix II tibial, mirror partial knee, cross fix meniscal …
  • KP Energy Ltd (539686):電力:M&Aディール及び事業提携情報
    Summary KP Energy Ltd (KP Energy) is an alternative energy company that offers power and wind energy solutions. The company provides services such as turnkey solutions, BOT basis services, land acquisition, project development, cost studies, site identification, capacity installations, engineer, pro …
  • General Electric Company:企業の戦略・SWOT・財務情報
    General Electric Company - Strategy, SWOT and Corporate Finance Report Summary General Electric Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Plexus Corp (PLXS):企業の財務・戦略的SWOT分析
    Plexus Corp (PLXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Canadian Natural Resources, Ltd.:企業の戦略・SWOT・財務分析
    Canadian Natural Resources, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Canadian Natural Resources, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • DRB-HICOM Defense Technologies Sdn Bhd:企業の戦略・SWOT・財務情報
    DRB-HICOM Defense Technologies Sdn Bhd - Strategy, SWOT and Corporate Finance Report Summary DRB-HICOM Defense Technologies Sdn Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Casey’s General Stores, Inc.:企業の戦略・SWOT・財務分析
    Casey's General Stores, Inc. - Strategy, SWOT and Corporate Finance Report Summary Casey's General Stores, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Grasim Industries Limited:企業の戦略・SWOT・財務分析
    Grasim Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Grasim Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • TUI AG (TUI1):企業の財務・戦略的SWOT分析
    TUI AG (TUI1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Ferguson Enterprises Inc:企業の戦略的SWOT分析
    Ferguson Enterprises Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Invuity Inc (IVTY):医療機器:M&Aディール及び事業提携情報
    Summary Invuity Inc (Invuity) is a medical technology company that develops and markets advanced surgical devices for the minimally invasive and minimal access procedures. The company offers illuminated surgical retractors, single-use handheld aspiration and universal drop-in intracavity illuminator …
  • Avadel Pharmaceuticals Plc (AVDL):製薬・医療:M&Aディール及び事業提携情報
    Summary Avadel Pharmaceuticals Plc (Avadel), formerly Flamel Technologies SA is a specialty pharmaceutical company, which develops and commercializes drugs for allergy, asthma, central nervous system (CNS) (narcolepsy), pain, respiratory diseases and diabetes. The company’s products are built on its …
  • Umeme Limited (UMEME):企業の財務・戦略的SWOT分析
    Umeme Limited (UMEME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Conn’S, Inc.:企業の戦略・SWOT・財務分析
    Conn'S, Inc. - Strategy, SWOT and Corporate Finance Report Summary Conn'S, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆